AlshaikhMK, GacuanD, GeorgeS, SharifM, BaHammamAS. Long-term follow-up of patients with narcolepsy-cataplexy treated with sodium oxybate (Xyrem)Clin Neuropharmacol, 34:1–4. 2011.
2.
AranA, EinenM, LingL, PlazziG, NishinoS, MignotE. Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: A retrospective study of 51 children. Sleep, 33:1457–1464. 2010.
3.
CostanzaCD, HernandezM, HernandezOJ, McDanielCH. GHB-induced delirium: A case report and review of the literature on gamma hydroxybutyric acid. Am J Drug Alcohol Abuse, 24:179–183. 1998.
RosenbergMH, DeerfieldLJ, BaruchEM. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: Recommendations for management. Am J Drug Alcohol Abuse, 29:487–496. 2003.
12.
RossettiAO, HeinzerRC, TaftiM, BuclinT. Rapid occurrence of depression following addition of sodium oxybate to modafinil. Sleep Med, 11:500–501. 2010.
13.
SullivanSS. Narcolepsy in adolescents. Adolesc Med State Art Rev, 21:542–555. 2010.
14.
TarabarAF, NelsonLS. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev, 23:45–49. 2004.
15.
The U.S. Xyrem® Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep, 25:42–49. 2002.
